Market Overview
The onychomycosis market was valued at USD 3,798.92 million in 2023 and is projected to reach USD 5,689.46 million by 2032, reflecting an impressive compound annual growth rate (CAGR) of 4.6% from 2024 to 2032.
What is Onychomycosis?
Onychomycosis is a fungal infection that affects the fingernails or toenails, leading to symptoms such as discoloration, thickening, and separation from the nail bed. This condition affects approximately 10% of the general population, but its prevalence increases significantly among older adults, with about 20% of individuals over 60 and 50% of those over 70 being affected. The rise in onychomycosis cases among the elderly is often linked to underlying conditions such as peripheral vascular disease, immune disorders, and diabetes mellitus. Individuals with diabetes are 1.9 to 2.8 times more likely to develop onychomycosis compared to the general population, while the prevalence in patients with HIV can range from 15% to 40%.
Key Market Stats
Here are some important statistics about the onychomycosis market:
- The market was valued at USD 3,798.92 million in 2023.
- It is expected to grow from USD 3,968.74 million in 2024 to USD 5,689.46 million by 2032.
- The market is anticipated to exhibit a CAGR of 4.6% during the forecast period.
Market Drivers and Trends
Several key factors are driving the growth of the onychomycosis market:
- Increased Research and Development: Companies and academic institutions are actively pursuing innovative and effective treatments for onychomycosis through various research and development initiatives aimed at enhancing safety and efficacy.
- Growing Geriatric Population: The rising number of elderly individuals worldwide is expected to boost demand for onychomycosis treatments, as aging often leads to a weakened immune system.
- Rise in Topical Treatments: Healthcare providers are increasingly favoring topical treatments based on factors such as the type of nail involvement, the organisms causing the infection, and patient-specific characteristics.
- Technological Advances: Innovations in technology, including laser treatments that utilize selective photothermolysis, are anticipated to further stimulate market growth.
Industry’s Prominent Players
Key players in the onychomycosis market include:
- Abbott
- Bausch Health Companies Inc.
- Cipla Inc.
- Merck & Co., Inc.
- Moberg Pharma AB
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
Geographical Landscape
North America currently holds the largest share of the onychomycosis market, driven by increasing incidence rates and robust government initiatives. Meanwhile, the Asia Pacific region is anticipated to experience the fastest growth rate during the forecast period, supported by a high prevalence of the condition.
Market Segmentation
Onychomycosis Market: Type-Based Outlook
- Distal Subungual Onychomycosis
- Proximal Subungual Onychomycosis
- White Superficial Onychomycosis
- Others
Onychomycosis Market: Treatment-Based Outlook
- Topical
- Oral
- Others
Onychomycosis Market: Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
About Polaris Market Research
Polaris Market Research is a global market research and consulting firm that specializes in delivering high-quality market intelligence and comprehensive business research services across various industries, including healthcare, technology, semiconductors, and chemicals. Our team consists of experts dedicated to providing valuable solutions to our clients.
Contact:
Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
Frequently Asked Questions
What is the projected growth rate of the onychomycosis market?
The onychomycosis market is projected to grow at a CAGR of 4.6% from 2024 to 2032.
What was the market size of onychomycosis in 2023?
The onychomycosis market was valued at USD 3,798.92 million in 2023.
Which region holds the largest market share?
North America currently holds the largest share of the onychomycosis market.
What factors are driving market growth?
Key drivers include increased research and development, a growing geriatric population, and advancements in treatment options.
Who are the major players in the onychomycosis market?
Prominent players include Abbott, Bausch Health Companies Inc., Cipla Inc., and Merck & Co., Inc.
